Scalp magnet reduces movement stiffness
- Trial ID
- NCT06840678
- Official Title
- Patogénesis Cortical De La Enfermedad De Parkinson: Efectos Corticales Y Corticoestriatales De La Estimulación Transcraneal Por Campo Magnético Estático En Pacientes Con Enfermedad De Parkinson
- Goal
- Scalp magnet reduces movement stiffness
- Phase
- PHASE1
- Status
- RECRUITING
- Sponsor
- Fundación de investigación HM
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson's Disease
- Interventions
- Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area
Plain-Language Summary
They're testing whether applying a static magnetic field to the supplementary motor area can change abnormal cortical and cortico-striatal activity that contributes to Parkinson's motor problems, as a first step toward a safe, noninvasive way to modulate those brain circuits. The approach is transcranial static magnetic field stimulation, a magnet placed over the SMA that can reduce or shift cortical excitability and network activity without inducing electrical currents like TMS, and it is being tested as an add-on to usual dopaminergic treatment rather than a replacement. Adults 18 to 80 with idiopathic Parkinson's who show a good response to dopaminergic meds (over 30% improvement on MDS-UPDRS-III) are eligible; people with MRI-incompatible implants, levodopa-induced dyskinesias, or major neuropsychiatric disorders are excluded.
Locations
- HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Móstoles, Madrid, Spain
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area. They're testing whether applying a static magnetic field to the supplementary motor area can change abnormal cortical and cortico-striatal activity that contributes to Parkinson's motor problems, as a first step toward a safe, noninvasive way to modulate those brain circuits. The approach is transcranial static magnetic field stimulation, a magnet placed over the SMA that can reduce or shift cortical excitability and network activity without inducing electrical currents like TMS, and it is being tested as an add-on to usual dopaminergic treatment rather than a replacement. Adults 18 to 80 with idiopathic Parkinson's who show a good response to dopaminergic meds (over 30% improvement on MDS-UPDRS-III) are eligible; people with MRI-incompatible implants, levodopa-induced dyskinesias, or major neuropsychiatric disorders are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 2 years and 11 months.